Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Emphasizes Efficiency In 522 Surveillance Order Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA is emphasizing the need for “early and ongoing” interaction between regulators and device companies targeted by the agency in Section 522 post-market surveillance orders in a draft guidance issued Aug. 16.

You may also be interested in...

FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order

The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.

FDA Considers Meeting With Firms Before Ordering Section 522 Studies

FDA’s device center seems agreeable to the concept of “pre-522” study meetings, raised by industry last week as a means to make the post-market study order process more efficient.

Regulatory News In Brief

Regulatory news includes new bills in the Senate, CDRH pact with LifeScience Alley and more.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts